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High inhaled oxygen concentration 
quadruples exhaled co in healthy 
volunteers monitored by a highly 
sensitive laser spectrometer
Vivien Brenckmann1,2, Irène Ventrillard3, Daniele Romanini3, Kévin Jaulin4, Pascale Calabrèse2 
& Raphaël Briot1,2
carbon monoxide (co) monitoring in human breath is the focus of many investigations as co could 
possibly be used as a marker of various diseases. Detecting CO in human breath remains a challenge 
because low concentrations (<ppm) must be selectively detected and short response time resolution 
is needed to detect the end expiratory values reflecting actual alveolar concentrations. A laser 
spectroscopy based instrument was developed (ProCeas) that fulfils these requirements. The aim of this 
study was to validate the use of a proceas for human breath analysis in order to measure the changes of 
endogenous exhaled CO (eCO) induced by different inspired fractions of oxygen (FiO2) ranging between 
21% and 100%. This study was performed on healthy volunteers. 30 healthy awaked volunteers 
(including asymptomatic smokers) breathed spontaneously through a facial mask connected to the 
respiratory circuit of an anesthesiology station. fio2 was fixed to 21%, 50% and 100% for periods of 
5 minutes. CO concentrations were continuously monitored throughout the experiment with a ProCeas 
connected to the airway circuit. The respiratory cycles being resolved, eCO concentration is defined 
by the difference between the value at the end of the exhalation phase and the level during inhalation 
phase. Inhalation of 100% FiO2 increased eco levels by a factor of four in every subjects (smokers 
and non smokers). eco returned in a few minutes to the initial value when fio2 was switched back 
to 21%. This magnification of eCO at 21% and 100% FiO2 is greater than those described in previous 
publications. We hypothesize that these results can be explained by the healthy status of our subjects 
(with low basal levels of eco) and also by the better measurement precision of proceas.
Monitoring the endogenous carbon monoxide in exhaled breath (eCO) is of growing interest in clinical studies. 
This rapid and non-invasive measurement may reveal various pathological conditions.
Carbon monoxyde (CO) has been extensively studied, as it is well known as a toxic gas in ambient air due to 
incomplete combustion of organic products. Beyond this external toxic effect, CO is normally produced endoge-
nously by the degradation of heme porphyrins to biliverdin and iron (bilirubin metabolism or heme catbolism). 
This reaction is catalyzed by the rate-limiting enzyme family of heme oxygenases (HO). Several sources of stress 
including inflammation and ischemia-reperfusion injury, dramatically increased expression of HO-1, the induc-
ible isoform, leading to increased levels of endogenous CO1. Thus endogenous CO is not the cause of the diseases 
but it could be an interesting marker to monitor closely. Endogenous CO is eliminated from the body in exhaled 
air via the normal respiratory process. CO concentration in exhaled air (i.e. eCO) is thus a good indicator of the 
actual values of this molecule in the body. The eCO level increases in several airways inflammatory diseases like 
asthma2, COPD3, and allergic rhinitis4. eCO is also increased in some systemic diseases such as severe sepsis 
occurring in cirrhotic patients5. Moreover it is a predictive marker of obliterative bronchiolitis which occurs after 
lung transplantation6.
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The increase in CO production, in turn, exerts anti-inflammatory, anti-apoptotic and anti-proliferative effects 
and limits ischemia-reperfusion injury consequences. For example, reduction of CO production (by inhibition of 
HO enzyme activity) after experimental lung ischemia-reperfusion, increases alveolar cell damage, recruitment 
of inflammatory cells, and lung edema. In contrast, inhalation of small concentrations of exogenous CO (100 
ppm to 500 ppm), reduces apoptosis, excretion of inflammatory mediators and pulmonary edema caused by 
ischemia-reperfusion injury1.
ECO concentrations in healthy subjects reach 1.5 ppm up to more than 10 ppm depending on smoking status 
of the subjects7. Some clinical studies require eCO continuous monitoring with a sensitive and reliable device 
allowing cycle to cycle variation measurements by high frequency sampling. This allows to accurately monitor 
the eCO deduced from the value measured at the end of the exhalation phase to which is subtracted the CO back-
ground measured during the inhalation phase. This background corresponds to CO concentration in inhaled gas 
that may be subject to change. As an example, in a clinical room, CO concentration in ambient air can vary daily 
in a typical range of 0.3 to 0.9 ppm. In medical gas supplies (medical air or oxygen) CO concentration is usually 
lower (<0.2 ppm) and more stable8. The recently developped laser spectroscopy technique named OF-CEAS (for 
Optical Feedback - Cavity Enhanced Absorption Spectroscopy), has been described in detail in previous publi-
cations8–10. The instrument implementing this technique, commercialized by the French company AP2E, goes 
under the denomination of ProCeas used further below. The OF-CEAS technique has the advantage, relative to 
others laser spectroscopy methods11 to offer an exceptionally low CO detection limit (typically 1 part per billion: 1 
ppb) over a short response time (about 1 second) and using a modest gas flow (0.15 L/min). Moreover, OF-CEAS 
provides real time measurements without the need for a periodic calibration. The instrument is compact and can 
be operated by non-specialists in a medical environment.
Since endogenous CO is rather slowly eliminated in exhaled air, and its elimination is accelerated by a high 
oxygen rate, high oxygen concentrations are clinically used as a treatment in severe CO poisoning. Hyperbaric 
oxygen therapy is broadly used for carbon monoxide poisoning although its efficacy and details of implemen-
tation remain controversial12,13. Increasing FiO2 was already used for studying variations of eCO in sponta-
neously breathing patients just before cardiac surgery14 and in mechanically ventilated patients under general 
anesthesia15,16.
The aim of this study is to test the relevance of the OF-CEAS technique to monitor eCO variations due to 
modified FiO2 in healthy volunteers. Additionally, we compared ProCeas real-time measurements with values 
obtained by sample analysis of exhaled gas with a standard electrochemical handheld sensor (MicroCO; VYaire).
Methods
A prospective monocentric clinical trial in adult healthy volunteers was conducted over a one-month period. The 
protocol was carried out in accordance with relevant guidelines and regulations of French law concerning persons 
participating in biomedical research. The study protocol was registered in ClinicalTrials.gov (ClinicalTrials.gov 
identifier: NCT01881945) and was approved by the French “Comity for Protection of People” (CPP of region 
South East 5) (registration number 2008-A00273-52). Thirty healthy volunteers participated to the experiment. 
Informed consent was obtained from each subject. For medical gas supply convenience, measurements took place 
in an operating room of the Grenoble University hospital. The healthy subjects, comfortably seated and perfectly 
awake, would breath at rest through a facial mask connected to the airway circuit of an anesthesiology station 
(Primus Dräger). This station was connected to the regular medical gas supply (air and oxygen) of the operating 
room. Once the subject was installed, he/she was required to hold the mask tightly against his/her face and asked 
to breath through the mask at a resting rate. Initially the mask was only connected to an antiparticule filter, so 
that the subject would breath ambient air. Then the mask and the filter were connected to the tubing circuit of 
the anesthesiology station. The airway circuit of the station was set in manual mode for spontaneous breathing 
(i.e. no mechanical ventilation) and on “open circuit” with a fresh gas flow rate sufficient to prevent rebreathing.
Different values of the inspired fraction of oxygen were applied through the control panel of the anesthesiol-
ogy station. Over a period of 30 minutes, eCO levels were recorded during different steps (ambient air, FiO2 21%, 
FiO2 50%, FiO2 100%). Each step had a five minute duration of steady-state duration.
eCO measurement by optical feedback cavity-enhanced absorption spectroscopy (OF-CEAS). 
This laser spectroscopy technique and its potential interest in clinical implementation have been described in 
details in previous publications8–11. Briefly, laser spectroscopy measurements of very low gas concentrations (less 
than 1 ppm for endogenous expired CO for a non-smoker patient) require a large light absorption path. As 
some other spectroscopy techniques, OF-CEAS exploits a resonant optical cavity that allows an effective optical 
absorption path length of several kilometers while the cavity is only one meter long (folded in two arms) and its 
volume is about 20 cm3. This allows very sensitive measurements with compact instruments and a small sampling 
volume. Additionally, OF-CEAS provides absolute concentration measurements of sufficient accuracy without 
any periodic calibration with certified gas mixtures. In contrast to the somewhat complex physics underlying 
OF-CEAS, its optical layout consists of few basic optical elements allowing for a compact and robust device. In 
this study we use an OF-CEAS analyzer (ProCeas) commercialized by the AP2Ecompany (Aix-en-Provence, 
France). This instrument, including electronics for laser control and data acquisition, fits inside a 19 inches rack 
and is perfectly adapted to a medical environment (Fig. 1). The ProCeas continuously measures CO concentra-
tion by extracting a flow of 0.15 L/min from the airway circuit of the anesthesiology station. Measurements are 
performed at a reduced pressure of 140 mbar in the optical cavity. The CO detection limit is about 1 ppb for an 
acquisition time of 0.2 second. (Fig. 2A). The response time is limited to 1 second by the gas exchange time in the 
cavity. For each eCO measurement, a zone of interest of about one minute of the cycle-to-cycle recorded curve 
was selected (Fig. 2B). An automatic computer analysis detected the maximum and minimum values of each 
cycle and calculate the difference, for each respiratory cycle, between inhaled and exhaled CO. This provides the 
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actual amount of endogenous CO produced by the organism, regardless of CO levels in ambient air or in medical 
gases supplied to the anesthesiology station. Another research group, using a close laser spectroscopy technic, 
coupled with eCO2 expirograms measured by capnography and laser spectroscopy, confirmed the true real-time 
detection of this technic17. It as to be noted that eCO exhalation profiles have a slightly different shape than the 
eCO2 profiles (due to its local production by airway epithelium) therefore showing a dependence on exhalation 
flow rate and breath-holding time.
eco measurement with an electrochemical sensor (Microco). All along the experiment we also 
measured eCO with a standard electrochemical fuel cell handheld sensor (MicroCO; VYaire Fig. 1). This instru-
ment is commonly used in smoking cessation clinical programs or for detection of CO poisoning. The compari-
son between the two devices was not the main goal of our study as, by construction, the two devices display very 
different characteristic and sensitivities. Indeed, the MicroCO resolution is 1 ppm with a response time below 
15 second. Comparison with the MicroCO is useful to illustrate the wide difference between today available med-
ical devices and the accuracy and speed attainable with a ProCeas laser spectrometer. The MicroCO device was 
Figure 1. eCO was measured by both ProCeas and MicroCO devices.
Figure 2. (A,B) eCO curves recorded with a ProCeas for a non-smoker healthy volunteer breathing medical 
air (21% FiO2). (A) eCO is monitored with a sampling frequency of 5 Hz (one measure every 0.2 second). 
(B) Maximum (expiration) and minimum (inspiration) values are automatically detected, cycle-to cycle, by 
automatic computer analysis. The maximum corresponds to the end-expiratory alveolar concentration of eCO 
and the minimum corresponds to the CO concentration in ambient air or medical gas. To calculate the actual 
eCO after correction of ambient CO, the software automatically subtracts, cycle by cycle, the minimum from the 
maximum.
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carefully calibrated before the experiments using a calibration gas containing 20 ppm of CO (from VYaire). For 
measurements, a sample of exhaled air was taken during mid-outbreath using a 60 mL syringe connected to a 
three-way valve placed in the airway circuit. The air in the syringe was then slowly expelled into the MicroCO. 
Each MicroCO measurement was performed three times, then results were averaged.
Statistical analysis. The sample-size estimation (NQuery Advisor 7.0 software; Statistical Solutions Ltd, 
Boston MA, USA) was based on data from previous publications15,16,18 with the aim to detect a difference of 5 ppm 
in eCO measured by ProCeas between FiO2 21% and FiO2 100% (patient being his own control) with a power of 
90% and a 2-tailed significance level of 0.05. For the comparison of eCO values taken at different FiO2, we used 
paired t test with Bonferroni correction for five repeated tests. Consequently, only p values < 0.01 were considered 
as significant. eCO results are finally presented as mean ± standard error (m ± S.E.). Correlation and reliability 
between ProCeas and MicroCO devices were tested by linear regression analysis and Blant and Altman plots.
ethics approval and consent to participate. The study protocol was approved by the French “Comity 
for Protection of People” (CPP of region South East 5) (registration number 2008-A00273-52). Only adults vol-
unteers participated to the experiment. Written consent was obtained from every subjects.
Results
30 healthy participants (29.7 ± 7.2 years old with a sex ratio of 53.7% of women) were included in this experiment. 
19 subjects were non-smokers whereas 11 subjects admitted smoking habits between 1 and 20 pack-years (mean: 
8.6 ± 1.8 pack-years). The time between the last cigarette and the moment of eCO measurement was also variable 
among the smokers (from 2 hours to 24 hours). CO concentration gas in the airway circuit was monitored in 
real time during all the 30 minutes breathing by the ProCeas analyzer. Measurements during inhalation phases 
allow to deduce the CO background in inhaled air that is cycle by cycle subtracted to the exhaled CO concentra-
tion values, as described above in the methods section. For accurate measurements monitoring the inhaled CO 
concentration is required as it varies at each FiO2 step: from a few ppb at FiO2 100% (pure medical oxygen) to a 
hundred of ppb at FiO2 21% (pure medical air) and has daily variations of hundreds ppb in ambient air (typically 
around 500 ppb). MicroCO was not sensitive enough to detect any CO in ambient air, neither in medical gases. 
eCO values measured while subjects breathed ambient air or medical air (FiO2 21%) were approximately similar 
(mean 5.225 ± 0.624 ppm) regardless of the moment when high FiO2 values were applied. Breathing high FiO2 
dramatically increased eCO (Table 1).
Subjects with smoking habits typically exhaled five times more eCO than non-smokers, regardless of FiO2 
(Fig. 3). However, whatever the initial eCO values in ambient air or medical air, applying FiO2 100% enhances 
eCO levels by a factor of four in smokers as well as in non smokers (Fig. 3). When FiO2 was switched back to 21%, 
eCO returned in a few minutes to the initial value measured before FiO2 elevation.
ProCeas values correlated well with MicroCO measurements (correlation coefficient r = 0,98) (Fig. 4A). 
However Bland – Altman analysis showed a mean bias of 2.2 ± 6.1 ppm with underestimation by MicroCO for 
low concentrations (MicroCO detection limit is 1 ppm) and overestimation by MicroCO for high CO levels 
(Fig. 4B).
Discussion
The main results of our study is that inhalation of 100% FiO2 increased eCO levels by a factor of four in every 
subjects (smokers and non smokers). Moreover the laser spectrometry analyzer ProCeas allows a precise and 
reliable cycle to cycle monitoring of endogenous exhaled CO. It measures accurately eCO elevations induced by 
FiO2 variations in healthy volunteers.
Comparison of different intruments. To our knowledge, this is the first study with a laser spectroscopy 
based analyzer, monitoring one-line, cycle-to-cycle, eCO changes due to FiO2 variations in healthy volunteers. 
Different instruments have been used to measure eCO concentration. Gas chromatography or mass spectrome-
try analyzers, do not allow real time analysis and are too heavy and bulky for a convenient utilization in medical 
environment. Thus, until now, electrochemical devices were most frequently used in clinical practice.
Electrochemical sensors. The detection thresholds of these sensors are generally above 1 ppm. Measuring actual 
alveolar eCO concentrations under various FiO2 is challenging with electrochemical devices. In volunteers 
this can be obtained from a single breath at forced expiration14. In mechanically ventilated patients, obtaining 
end-tidal gas samples requires to stop the ventilation in end-inspiration phase, clamp and disconnect the endotra-
cheal tube from the ventilator, then released the clamp so that all gas from the lungs is exhaled passively through 
Ambient air Medical air
Medical gas 
mixture
Medical pure 
oxygen Medical air
Time from beginning of 
experiment 5 min. 10 min. 15 min. 20 min. 25 min.
FiO2 21% 21% 50% 100% 21%
Exhaled CO (ppm) 4.98 ± 1.06 5.20 ± 1.08 9.30 ± 1.82 * 20.51 ± 4.08 ** 5.50 ± 1.14 *
Table 1. Exhaled Carbon Monoxide values measured by the ProCeas in healthy volunteers (smokers and non-
smokers together). **p < 0.001 Exhaled CO with FiO2 100% versus every other situation. *p < 0.01 Exhaled CO 
with FiO2 50% versus ambient air or medical air (FiO2 21%). Comparisons by paired t test, for n = 30.
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the CO monitor to residual functional capacity18. Other authors collected exhaled breath at the outlet of the venti-
lator and either measured averaged eCO concentrations15, or picked-up highest eCO (as end-tidal values) among 
all collected data16. Compared to these methods, our one-line, cycle-to-cycle monitoring with the ProCeas, allows 
5 measurements per second (5 Hz acquisition rate) and resolves each respiratory cycle. In our data, eCO level 
was lowest (1.71 ± 0.09 ppm) in non-smoker subjects at 21% FIO2. Such concentrations are close to the detection 
limit of the MicroCO. The range of eCO concentrations we measured at various FiO2 was roughly consistent with 
values found in other publications14–16,18. However, in our data, eCO measured by ProCeas almost quadrupled 
between 21% and 100% FiO2 whatever group being considered (smokers or non-smokers). This increase is greater 
than in other studies. It is also grater than our data with MicroCO which only detects a 2-fold eCO increase in 
non-smoker subjects breathing pure oxygen. It may be attributed to teh high sensitivity and the better resolution 
of the respiratory cycle of our measurements, that allows to accurately measure end-tidal values and also to sub-
tract cycle by cycle the inhaled level of CO to estimate correctly endogenous CO production.
Laser spectrometers. Over the two last decades, optical laser spectrometers started being used for eCO meas-
urement11. These devices are almost maintenance free and can operate continuously for long time periods. In 
2000 Zegdi et al.15 published the first study using an infrared CO analyzer (CO 2000, Sérès, La Duranne, France) 
to measure eCO variations due to FiO2 elevation, in mechanically ventilated critically ill patients. This study dis-
played very low eCO values compare to our data and to other publications14,16,18. The explanation is probably that 
owing to the long response time of the CO 2000 device (70 s), only averaged eCO concentrations were measured 
rather than alveolar (end-tidal) concentrations. These measurements could not be performed on-line but exhaled 
breath had to be collected in bags placed at the outlet of the ventilator before analysis.
Other laboratory prototypes have been developed using various laser spectroscopy techniques to measure CO 
in exhaled breath. A laser spectrometer exploiting resonant cavity with a technique very close to the OF-CEAS 
(named cavity ring-down spectroscopy), demonstrates similarly low detection limit (1ppb in 1 second),on-line as 
Figure 3. eCO measured by ProCeas in smokers (n = 11) and non-smoker (n = 19) subjects Values are given 
from the five minute duration of the steady-state after FiO2 changes. †p < 0.001 eCO with FiO2 100% versus 
every other situations in smokers. **p < 0.001 eCO with FiO2 100% versus every other situations in non-smoker 
subjects. *p < 0.01 eCO with FiO2 50% versus ambient air or medical air (FiO2 21%) in non-smoker subjects. 
Comparisons by paired t test.
Figure 4. (A,B) Comparison of ProCeas and MicroCO measurements. (A) Correlation scatter plot; correlation 
represents the relationship between dataset; correlation coefficient is given as r. (B) Bland-Altman plots; eCO 
are given in ppm; vertical axis shows the eCO difference between the compared devices; mean eCO on the 
horizontal axis refers to the average of the eCO values measured by both devices.
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well, but with a larger gas flow (0.7 L/min) extracted from the gas line for the laser analyzer19 So far, this research 
group validated the accuracy of their eCO measurements in few subjects and various situations: one smoker ver-
sus two non-smokers19, ten healthy volunteers practicing exercise20. However due to the use of a bulky laser(CO 
laser), unlike the ProCEAS, this system is a laboratory analyzer and is not transportable in medical environments. 
Compact analyzers adapted for eCO detection have been recently developed, based on the use of a multipass cell 
to enhance the light absorption path rather than a resonant optical cavity as used in OF-CEAS. Contrary to cavity 
enhanced techniques, the use of a multipass cell requires regular calibration (such as the commercial CO 2000 
device used by Zegdi et al., calibrated every week). Despite the lower absorption path of a multipass cell, the use 
of new semi-conductor lasers (QCL and ICL in the mid infrared range where CO absorption may be stronger) 
allows the development of compact and sensitive analyzers. A detection limit as low as 7 ppb for an integration 
time of 1 second was achieved by Pakmanesh et al.21. Here, as for the ProCEAS, the response time is limited by 
the gas exchange time in the cell. The small multipass cell volume (47 mL) and the reduced pressure (20mbar) 
allows a gas exchange time of 1.7 s, that could be even reduced below 1 second by increasing the flow from 33 mL/
min (value reported in21) to 100 mL/min. In comparison, the ProCeas operates at a sampling flow of 150 mL/min, 
flow that can be extracted from a ventilator gas line. More recently, Ghorbani et al.22 developed an instrument for 
eCO measurement that allows to resolve breath-cycle with a lower detection limit (~3 ppb in 1 second). With this 
device, different exhalation profile shapes are studied and a mathematical model is proposed to differentiate the 
CO gas exchange parameters between airways and alveoli. However, to reach such precision and resolution levels, 
this device needs to sample the gas with a flow of 3 L/min that has to be subtracted from the airway circuit17. Such 
flows represents almost the totality of normal human breath (tidal volume) at rest and is incompatible with an 
airway ventilator system as used in the work reported here.
tobacco and eco. In our data, any subject having recently smoked showed higher eCO levels than 
non-smokers. This effect is well known and is used to control actual tobacco consumption in clinical programs 
for smoke cessation23.
oxygen and eco. We found a systematic rise in eCO while increasing FiO2. eCO quadrupled between 21% 
and 100% FiO2 whatever was basal eCO level of each subject (smokers or non-smokers). eCO returned to basal 
values after FiO2 was switched back from 100% to 21%. This phenomenon is classically described in several pub-
lications14–16,18 within a broad spectrum of eCO values at comparable FiO2.
Schober et al.18 using an electrochemical sensor, measured eCO variation due to oxygen variation in volun-
teers. eCO values increased from 10.7 ± 5.9 ppm (21% FiO2) to 16.0 ± 6.0 ppm (100% FiO2). They also measured 
eCO in patients undergoing surgery, before and after pre-oxygenation for anesthesia, and after oro-tracheal intu-
bation. Similarly to volunteers, in eCO increased from 7.1 ± 6.1 to 16.4 ± 8.6 ppm after 10 min pre-oxygenation 
with pure oxygen. Oro-tracheal intubation enhances this increased eCO up to 26.1 ± 13.1 ppm.
The same research group performed the same kind of measurements, just before anaesthesia, in 19 patients 
scheduled for cardiac surgery. Oxygen inhalation resulted in an increase in eCO levels from 8.6 ± 4.9 to 16.7 ± 9.4 
ppm14. Adachi et al.16 studied (with an electrochemical sensor) the effect of FiO2 variations on exhaled CO, in thirty 
patients under general anaesthesia who underwent elective operations. They, all the same, found an eCO increase 
with high FiO2 (from 3.35 ± 0.62 ppm in basal value up to 7.57 ± 1.49 ppm under 100% FiO2). Zegdi et al.15  
using an infrared CO analyzer, measured eCO variations due to FiO2 elevation, in nine mechanically ventilated 
critically ill patients. These authors described also a rise in eCO with pure oxygen (from 0.63 ± 0.13 ppm in basal 
value up to 1.54 ± 0.16 ppm under 100% FiO2)
In our study, the amplitude of the eCO increase we measured (4 fold increase) is larger than those described 
in all these previous publications.
Various clinical situations and possible lack of precision of instruments may explain the discrepancies. Indeed 
most of these studies employed electrochemical devices. Nonetheless, a marked elevation of eCO with increasing 
FiO2 is systematically found in the literature. At 100% FiO2 all studies showed an eCO increase by a factor 2 or 3 
compared to basal levels. However frequently, basal values, in those series, are higher than found in our volunteers. 
Most of those previous publications concerned critically ill patients, or undergoing surgery, under mechanical ven-
tilation. In Zegdi et al. study15 patients were all in intensive care unit and their “basal status” was a mechanical ven-
tilation with 50% FiO2. This may perhaps explain the smaller difference (compare to ours) in eCO increase between 
their basal status and pure oxygen administration. Our healthy subjects (even if including non-symptomatic smok-
ers) had probably less airways inflammation than those patients. Because eCO is elevated in many inflammatory 
situations, this could explain why basal eCO levels were higher in other series than in our study.
Mechanisms of eco increase under high fio2. eCO elevation while increasing FiO2 may be due to a 
displacement of pre-existing CO from its hemoglobin bound. It could also originate as new CO production by 
hemoxygenase HO-1 induction. The few previous clinical studies investigating eCO changes while breathing 
oxygen-enriched air are in favor of the theory of CO displacement from hemoglobin. In Zegdi et al. study15 eCO 
rose markedly to a transient peak before returning to baseline values after seven hours of 100% FiO2. Schober et al.14  
measured arterial oxygen tension (PaO2) and arterial carboxy-hemoglobin levels (CO-Hb), in mechanically ven-
tilated patients. They showed a correlation between PaO2 and eCO levels which is in favor of the displacement 
of CO from hemoglobin bond. However, they failed to find a correlation between eCO concentrations and arte-
rial CO-Hb levels. Adachi et al.16 have shown a decrease of blood CO-Hb concentrations over time, correlated 
to a return of eCO to the baseline (and even lower the baseline level) after four hours of ventilation at 75% 
FiO2. This findings argues in favor the CO displacement hypothesis. However, deleterious effects of high oxygen 
concentrations are known and hyperoxia is used to induce an experimental acute lung injury in several animal 
models24. Hyperoxia may provoke an over-expression of HO-1 that in turn brings about an overproduction of 
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carbon monoxide25. Possibly this mechanism might account for a part of the eCO we measured in our subjects 
but we have not measured HO-1 in our healthy volunteers. As our subjects were only exposed to 100% FiO2 for 
a very short period (five minutes) we think that inflammatory reactions due to hyperoxia probably did not have 
sufficient time to occur nor did the production of CO from the degradation of the heme molecules. Therefore we 
hypothesis that our eCO increase under pure oxygen is mostly due to CO displacement from hemoglobin.
Limits of the study. The carbon monoxide content in ambient air was not taken into account when record-
ing MicroCO values, however this device was not sensitive enough to detect any CO in ambient air or in medical 
gases. No blood sample was collected during our experiments on healthy volunteers. Measurement of inducible 
hemeoxygenase (HO-1), carboxyhemoglobin (Hb-CO) or pro-inflammatory cytokines could have been of inter-
est. However, the main goal of the study was to test the accuracy of the ProCeas in clinical setting rather than 
questioning the physiological CO production pathways. The study was conducted in healthy volunteers and not 
on critically ill patients whose profile of endogenous CO production is probably different from physiological 
pathways, due to inflammation and others pathological mechanisms.
future applications. CO is increasingly being accepted as a cytoprotective and homeostatic molecule with 
important signaling capabilities in physiological and pathophysiological situations1,26. Being able to monitor on 
line and precisely the endogenous production of CO could be of high interest in several clinical situations such as 
those concerning airways inflammation (COPD, Asthma, Cystic Fibrosis, lung transplantation). Some research 
teams also use eCO levels to estimate accurately red blood cell lifespan and study several forms of anemia27. As 
another application, the precision of the OF-CEAS technique allows to selectively measure lung CO production 
in an experimental ex vivo pig lung perfusion (EVLP) model in order to develop noninvasive identification of the 
most IR injured lungs10. One of our ongoing study is currently evaluating eCO measurements in human EVLP 
procedures in a clinical lung transplantation program.
conclusion
The ProCeas instrument, based on the OF-CEAS technique, demonstrated its suitability in clinical setting for 
on-line cycle-to-cycle monitoring of endogenous exhaled CO. In an operating room environment, ProCeas 
measured a four fold increase in eCO in healthy volunteers (smokers and non-smokers) breathing pure oxygen 
compared to air. This amplitude of eCO increase between 21% and 100% FiO2 is greater than those described in 
previous publications. We hypothesize that the precision of measurements and a better respiratory cycle resolu-
tion of ProCeas explains these results.
Data Availability
The datasets used and analysed during the current study are available from the corresponding author on reason-
able request.
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